LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY

被引：0
|
作者：
Banerji, A.
Hao, J.
Yu, M.
Bernstein, J.
Johnston, D.
Riedl, M.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2020年 / 125卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P150
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [1] LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Riedl, M.
    Cicardi, M.
    Hao, J.
    Lu, P.
    Li, H.
    Manning, M.
    Bernstein, J.
    Busse, P.
    Tachdjian, R.
    Gower, R.
    Wedner, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S31
  • [2] Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final Results From the HELP Open-Label Extension Study
    Paes, Kim
    Bernstein, Jonathan
    Longhurst, Hilary
    Aygoren-Pursun, Emel
    Ren, Hong
    Craig, Timothy
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB145 - AB145
  • [3] An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
    Riedl, Marc A.
    Bernstein, Jonathan A.
    Craig, Timothy
    Banerji, Aleena
    Magerl, Markus
    Cicardi, Marco
    Longhurst, Hilary J.
    Shennak, Mustafa M.
    Yang, William H.
    Schranz, Jennifer
    Baptista, Jovanna
    Busse, Paula J.
    CLINICAL AND TRANSLATIONAL ALLERGY, 2017, 7
  • [4] Long-term prevention of attacks with lanadelumab across subgroups of patients with hereditary angioedema (HAE): final results from the HELP open-label extension study
    Maurer, M.
    Bernstein, J. A.
    Jacobs, J.
    Lumry, W. R.
    Ren, H.
    Soteres, D.
    Yu, M.
    Martinez-Saguer, I
    ALLERGY, 2021, 76 : 10 - 10
  • [5] Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Long-Term Prophylaxis Use: Interim Results From the HELP Open-Label Extension Study
    Paes, Kim
    Craig, Timothy
    Bernstein, Jonathan
    Longhurst, Hilary
    Aygoren-Pursun, Emel
    Nurse, Christina
    Zuraw, Bruce
    Jacobs, Joshua
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB102 - AB102
  • [6] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
    Cohen, Stanley
    Pablos, Jose L.
    Zhang, Nan
    Rizzo, Warren
    Muller, Gerhard
    Padmanaban, Devi
    Kivitz, Alan
    Matsumoto, Alan K.
    Kaur, Primal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [7] LANADELUMAB EFFICACY AFTER SWITCHING FROM PLACEBO: RESULTS FROM THE HELP AND HELP OPEN-LABEL EXTENSION STUDIES
    Tachdjian, R.
    Anderson, J.
    Busse, P.
    Johnston, D.
    Kiani, S.
    Nurse, C.
    Paes, K.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S38 - S38
  • [8] Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
    Vermeire, Severine
    Chiorean, Michael
    Panes, Julian
    Peyrin-Biroulet, Laurent
    Zhang, Jinkun
    Sands, Bruce E.
    Lazin, Krisztina
    Klassen, Preston
    Naik, Snehal U.
    Cabell, Christopher H.
    Sandborn, William J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (06) : 950 - 959
  • [9] Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study
    Chiorean, Michael
    Vermeire, Severine
    Panes, Julian
    Peyrin-Biroulet, Laurent
    Zhang, Jinkun
    Sands, Bruce E.
    Lazin, Krisztina
    Cabell, Chris H.
    Naik, Snehal U.
    Klassen, Preston
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S445 - S446
  • [10] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY
    Kivitz, A.
    Wells, A. F.
    Vargas, J. Ignacio
    Baraf, H. S. B.
    Rischmueller, M.
    Klaff, J.
    Khan, N.
    Li, Y.
    Carter, K.
    Friedman, A.
    Durez, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 620 - 621
12345